ChondroGene published paper ´Human genome project and cardiovascular disease genes´

In landmark textbook ´Molecular Basis of Cardiovascular Disease´

28-Jul-2004

Toronto. ChondroGene Limited announced publication of a timely review paper entitled, human genome project and cardiovascular disease genes authored by Dr. C.C. Liew, Chief Scientific Officer and co-founder of ChondroGene Limited and Dr. Victor J. Dzau, Chancellor for Health Affairs at Duke University, President and CEO of the Duke University Health System, and Senior Scientific Advisor to ChondroGene. This paper appears in the long-awaited Second Edition of Kenneth Chien's landmark textbook, Molecular Basis of Cardiovascular Disease: A Companion to Braunwald's Heart Disease.

Dr. Liew's chapter describes some of the major techniques and technologies developed for the Human Genome Project. He traces these technologies as they have been applied in tissue specific studies, including Dr. Liew's own cardiovascular gene discovery research. Such studies and related genomic projects have identified a number of genes linked to a variety of cardiac and cardiovascular conditions.

Dr. Liew, who was Professor of Clinical Biochemistry and Medicine at the University of Toronto and Director of the Cardiac Gene Unit at the Banting Institute, Toronto Hospital, University Health Network, is considered by many to be the father of cardiovascular genomics. He was one of the first to study and identify the tissue specific genes involved in the cardiovascular system. His findings were published in a seminal paper in the journal Circulation in 1997, entitled A Genome-Based Resource for Molecular Cardiovascular Medicine: Toward a Compendium of Cardiovascular Genes. In 1999, based on this work and his reputation in the field, he was invited by Harvard Medical School at Harvard University to establish and direct the Cardiovascular Genome Unit at Brigham and Women's Hospital in Boston.

At ChondroGene, Dr. Liew has been instrumental in applying his techniques for tissue specific gene expression studies to cartilage tissue. This work has led to the Company's progress in understanding the genes and pathways involved in osteoarthritis (OA) as the company develops new drug targets and diagnostics for OA.

While conducting research in tissue specific gene expression, Dr. Liew developed a hypothesis, since named the "Sentinel Principle", to monitor and discern an individual's state of health. He has since used the Sentinel Principle to detect, diagnose and stage a broad range of human disease. The simple and elegant idea behind the Sentinel Principle is that circulating blood reflects what is happening throughout the body and that by using appropriate techniques, it should be possible to detect this information in blood samples. This theory, presented in 2003 in the Journal of Molecular and Cellular Cardiology, in a paper entitled, Gene profiling identifies secreted protein transcripts from peripheral blood cells in coronary artery disease, has since been confirmed by ChondroGene in OA and in other diseases. The Sentinel Principle is the basis for ChondroGene's blood-based molecular diagnostic technology.

https://www.bionity.com/en/news/38816/chondrogene-published-paper-human-genome-project-and-cardiovascular-disease-genes.html